UA77408C2 - Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof - Google Patents
Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof Download PDFInfo
- Publication number
- UA77408C2 UA77408C2 UA2003098168A UA2003098168A UA77408C2 UA 77408 C2 UA77408 C2 UA 77408C2 UA 2003098168 A UA2003098168 A UA 2003098168A UA 2003098168 A UA2003098168 A UA 2003098168A UA 77408 C2 UA77408 C2 UA 77408C2
- Authority
- UA
- Ukraine
- Prior art keywords
- group
- alkyl
- formula
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 239000003475 metalloproteinase inhibitor Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- -1 p-ethoxyphenyl Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 102000005741 Metalloproteases Human genes 0.000 claims description 23
- 108010006035 Metalloproteases Proteins 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 22
- 125000006413 ring segment Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 6
- JGSLKNWXPRDWBA-UHFFFAOYSA-N 2-methylidene-1h-pyridine Chemical compound C=C1NC=CC=C1 JGSLKNWXPRDWBA-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 19
- 102100027998 Macrophage metalloelastase Human genes 0.000 abstract description 13
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 125000001188 haloalkyl group Chemical group 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 15
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical group O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 102100030411 Neutrophil collagenase Human genes 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 125000004404 heteroalkyl group Chemical group 0.000 description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 10
- 102000003390 tumor necrosis factor Human genes 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 8
- 229940124761 MMP inhibitor Drugs 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100030416 Stromelysin-1 Human genes 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010014561 Emphysema Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000006168 tricyclic group Chemical group 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 5
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710118230 Neutrophil collagenase Proteins 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 5
- 125000005157 alkyl carboxy group Chemical group 0.000 description 5
- 125000004103 aminoalkyl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 101710108790 Stromelysin-1 Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 235000012501 ammonium carbonate Nutrition 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 150000001469 hydantoins Chemical class 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- CZYMNCPDEOQKIL-UHFFFAOYSA-N 5-(aminomethyl)imidazolidine-2,4-dione Chemical compound NCC1NC(=O)NC1=O CZYMNCPDEOQKIL-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 150000001356 alkyl thiols Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 125000005462 imide group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 125000006178 methyl benzyl group Chemical group 0.000 description 3
- 125000006384 methylpyridyl group Chemical group 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 150000004763 sulfides Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000016284 Aggrecans Human genes 0.000 description 2
- 108010067219 Aggrecans Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 208000018035 Dental disease Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102000056189 Neutrophil collagenases Human genes 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 208000014151 Stomatognathic disease Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000006103 sulfonylation Effects 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 230000004572 zinc-binding Effects 0.000 description 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- QPRATAOCXWOIPO-UHFFFAOYSA-N 2-nitroethene-1,1-diamine Chemical compound NC(N)=C[N+]([O-])=O QPRATAOCXWOIPO-UHFFFAOYSA-N 0.000 description 1
- SFWWGMKXCYLZEG-UHFFFAOYSA-N 3-methylmorpholine Chemical compound CC1COCCN1 SFWWGMKXCYLZEG-UHFFFAOYSA-N 0.000 description 1
- IXBZJPOQTSAQHW-UHFFFAOYSA-N 4-phenylbutane-2-thione Chemical compound CC(=S)CCC1=CC=CC=C1 IXBZJPOQTSAQHW-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102000034473 Adamalysin Human genes 0.000 description 1
- 108030001653 Adamalysin Proteins 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 241001516584 Andrya Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- 102000034498 Astacin Human genes 0.000 description 1
- 108090000658 Astacin Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
- 101001011884 Homo sapiens Matrix metalloproteinase-15 Proteins 0.000 description 1
- 101001011886 Homo sapiens Matrix metalloproteinase-16 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101150010457 SAS5 gene Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005362 aryl sulfone group Chemical group 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- KWBIXTIBYFUAGV-UHFFFAOYSA-N ethylcarbamic acid Chemical compound CCNC(O)=O KWBIXTIBYFUAGV-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical group CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 102000047338 human MMP12 Human genes 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GTMQOMPXVQGITC-UHFFFAOYSA-N n-[(2,5-dioxoimidazolidin-4-yl)methyl]-5-pyridin-2-ylthiophene-2-sulfonamide Chemical compound O=C1NC(=O)NC1CNS(=O)(=O)C1=CC=C(C=2N=CC=CC=2)S1 GTMQOMPXVQGITC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- ISTGQSQWSKCNFJ-UHFFFAOYSA-N tert-butyl n-ethylcarbamate Chemical compound CCNC(=O)OC(C)(C)C ISTGQSQWSKCNFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D403/00โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D233/00โHeterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54โHeterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66โHeterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72โTwo oxygen atoms, e.g. hydantoin
- C07D233/76โTwo oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78โRadicals substituted by oxygen atoms
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00โDrugs for disorders of the alimentary tract or the digestive system
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00โDrugs for disorders of the alimentary tract or the digestive system
- A61P1/02โStomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00โDrugs for disorders of the alimentary tract or the digestive system
- A61P1/04โDrugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00โDrugs for disorders of the alimentary tract or the digestive system
- A61P1/16โDrugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00โDrugs for disorders of the respiratory system
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00โDrugs for disorders of the respiratory system
- A61P11/02โNasal agents, e.g. decongestants
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00โDrugs for disorders of the respiratory system
- A61P11/06โAntiasthmatics
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00โDrugs for disorders of the urinary system
- A61P13/12โDrugs for disorders of the urinary system of the kidneys
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00โDrugs for genital or sexual disorders; Contraceptives
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00โDrugs for dermatological disorders
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00โDrugs for dermatological disorders
- A61P17/02โDrugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00โDrugs for dermatological disorders
- A61P17/04โAntipruritics
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00โDrugs for dermatological disorders
- A61P17/06โAntipsoriatics
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00โDrugs for skeletal disorders
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00โDrugs for skeletal disorders
- A61P19/02โDrugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00โDrugs for skeletal disorders
- A61P19/04โDrugs for skeletal disorders for non-specific disorders of the connective tissue
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00โDrugs for skeletal disorders
- A61P19/06โAntigout agents, e.g. antihyperuricemic or uricosuric agents
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00โDrugs for skeletal disorders
- A61P19/08โDrugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00โDrugs for skeletal disorders
- A61P19/08โDrugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10โDrugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00โDrugs for disorders of the nervous system
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00โDrugs for disorders of the nervous system
- A61P25/02โDrugs for disorders of the nervous system for peripheral neuropathies
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00โDrugs for disorders of the nervous system
- A61P25/28โDrugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00โDrugs for disorders of the senses
- A61P27/02โOphthalmic agents
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00โNon-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00โDrugs for disorders of the metabolism
- A61P3/08โDrugs for disorders of the metabolism for glucose homeostasis
- A61P3/10โDrugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00โAntineoplastic agents
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00โAntineoplastic agents
- A61P35/04โAntineoplastic agents specific for metastasis
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00โDrugs for immunological or allergic disorders
- A61P37/08โAntiallergic agents
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00โDrugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00โDrugs for disorders of the blood or the extracellular fluid
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00โDrugs for disorders of the blood or the extracellular fluid
- A61P7/02โAntithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00โDrugs for disorders of the cardiovascular system
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00โDrugs for disorders of the cardiovascular system
- A61P9/04โInotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- AโHUMAN NECESSITIES
- A61โMEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61PโSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00โDrugs for disorders of the cardiovascular system
- A61P9/10โDrugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D233/00โHeterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54โHeterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66โHeterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72โTwo oxygen atoms, e.g. hydantoin
- C07D233/76โTwo oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D401/00โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D401/00โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D403/00โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D403/00โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12โHeterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D405/00โHeterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02โHeterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12โHeterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D405/00โHeterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14โHeterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D409/00โHeterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14โHeterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D417/00โHeterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14โHeterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- CโCHEMISTRY; METALLURGY
- C07โORGANIC CHEMISTRY
- C07DโHETEROCYCLIC COMPOUNDS
- C07D471/00โHeterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02โHeterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04โOrtho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0100902A SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Compounds |
PCT/SE2002/000478 WO2002074751A1 (fr) | 2001-03-15 | 2002-03-13 | Inhibiteurs des metalloproteinases |
Publications (1)
Publication Number | Publication Date |
---|---|
UA77408C2 true UA77408C2 (en) | 2006-12-15 |
Family
ID=20283374
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2003098168A UA77408C2 (en) | 2001-03-15 | 2002-03-13 | Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof |
UA2003098171A UA78502C2 (en) | 2001-03-15 | 2002-03-13 | Metalloproteinase inhibitors, use thereof, and pharmaceutical composition based thereon |
UA2003098170A UA77667C2 (en) | 2001-03-15 | 2002-03-13 | Metalloproteinase inhibitors, pharmaceutical composition and use thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2003098171A UA78502C2 (en) | 2001-03-15 | 2002-03-13 | Metalloproteinase inhibitors, use thereof, and pharmaceutical composition based thereon |
UA2003098170A UA77667C2 (en) | 2001-03-15 | 2002-03-13 | Metalloproteinase inhibitors, pharmaceutical composition and use thereof |
Country Status (33)
Country | Link |
---|---|
US (8) | US7427631B2 (fr) |
EP (4) | EP1370534A1 (fr) |
JP (4) | JP4390457B2 (fr) |
KR (4) | KR20030082986A (fr) |
CN (5) | CN101602731A (fr) |
AR (2) | AR035443A1 (fr) |
AT (3) | ATE493406T1 (fr) |
AU (2) | AU2002237626B2 (fr) |
BR (3) | BR0207984A (fr) |
CA (3) | CA2440473C (fr) |
CY (1) | CY1107525T1 (fr) |
CZ (3) | CZ20032499A3 (fr) |
DE (3) | DE60213216T2 (fr) |
DK (1) | DK1370556T3 (fr) |
EE (3) | EE05364B1 (fr) |
ES (3) | ES2267986T3 (fr) |
HK (3) | HK1091492A1 (fr) |
HU (3) | HUP0400194A3 (fr) |
IL (5) | IL157657A0 (fr) |
IS (3) | IS6943A (fr) |
MX (3) | MXPA03008191A (fr) |
MY (2) | MY136789A (fr) |
NO (3) | NO20034044L (fr) |
NZ (3) | NZ528106A (fr) |
PL (3) | PL205315B1 (fr) |
PT (1) | PT1370556E (fr) |
RU (3) | RU2285695C2 (fr) |
SE (1) | SE0100902D0 (fr) |
SI (1) | SI1370556T1 (fr) |
SK (3) | SK10952003A3 (fr) |
UA (3) | UA77408C2 (fr) |
WO (3) | WO2002074751A1 (fr) |
ZA (4) | ZA200306732B (fr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ใใชในใใซใผใใคใคใผใบ ในใฏใคใ ใซใณใใใผ | ใใใชใใฏในใกใฟใญใใญใใใผใผๅใณ๏ผใพใใฏ๏ผด๏ผฎ๏ผฆโฮฑ่ปขๆ้ ต็ด ๏ผ๏ผด๏ผก๏ผฃ๏ผฅ๏ผใฎ้ปๅฎณๅคใจใใฆใฎใใใณใใคใณๅใณ้ข้ฃ่ค็ด ็ฐๅๅ็ฉ |
SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
SE0202693D0 (sv) * | 2002-09-11 | 2002-09-11 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
EP1546109A4 (fr) * | 2002-10-04 | 2005-11-09 | Bristol Myers Squibb Co | Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace) |
JP4866610B2 (ja) | 2003-08-18 | 2012-02-01 | ๅฏๅฃซใใคใซใ ใใกใคใณใฑใใซใซใบๆ ชๅผไผ็คพ | ใใชใธใซใใใฉใใใญใใชใธใณ้กใใใณใใชใธใซใใใชใธใณ้ก |
US20050203156A1 (en) * | 2004-03-12 | 2005-09-15 | Wyeth | Hydantoins having RNase modulatory activity |
US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
JP2008512463A (ja) * | 2004-09-08 | 2008-04-24 | ใใผใคใบ ใฟใฆใณ ใใทใงใใซ ใชใตใผใ ใในใใฟใซ | ใใใชใใฏในใกใฟใญใใญใใคใใผใผโ๏ผ๏ผใซ้ข้ฃใใ็ณธ็ไฝๅบๅบ่็พๆฃใฎๆฒป็ |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
EP1830837B1 (fr) * | 2004-09-20 | 2013-09-04 | Xenon Pharmaceuticals Inc. | Derives heterocycliques pour le traitement de maladies induites par des enzymes stearoyl-coadesaturases |
JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ใผใใณใปใใกใผใใทใฅใผใใฃใซใซใบใปใคใณใณใผใใฌใคใใใ | ่ค็ด ็ฐ่ชๅฐไฝใใใณๆฒป็่ฌใจใใฆใฎใใใใฎไฝฟ็จ |
JP4958785B2 (ja) | 2004-09-20 | 2012-06-20 | ใผใใณใปใใกใผใใทใฅใผใใฃใซใซใบใปใคใณใณใผใใฌใคใใใ | ่ค็ด ็ฐ่ชๅฐไฝใใใณในใใขใญใคใซโ๏ผฃ๏ฝ๏ผกใใตใใฅใฉใผใผใคใณใใใฟใผใจใใฆใฎใใใใฎไฝฟ็จ |
BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibiรงรฃo de estearoil-coa-desaturase |
EP2266569A3 (fr) | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Dรฉrivรฉs hรฉtรฉrocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase |
JP2008513515A (ja) | 2004-09-20 | 2008-05-01 | ใผใใณใปใใกใผใใทใฅใผใใฃใซใซใบใปใคใณใณใผใใฌใคใใใ | ่ค็ด ็ฐ่ชๅฐไฝใใใณๆฒป็่ฌใจใใฆใฎใใใใฎไฝฟ็จ |
GB0427403D0 (en) * | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
WO2006099598A2 (fr) * | 2005-03-16 | 2006-09-21 | Sensus Metering Systems Inc. | Procede, systeme, appareil et programme informatique permettant de determiner un emplacement physique d'un capteur |
AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
WO2007078335A2 (fr) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Inhibiteurs de biaryl-azote-heterocycle de lta4h pour traiter l'inflammation |
AR059036A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
TW200800954A (en) * | 2006-03-16 | 2008-01-01 | Astrazeneca Ab | Novel crystal modifications |
TW200740769A (en) * | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
KR101293500B1 (ko) * | 2006-05-12 | 2013-08-07 | ์์ค์ฒด์ ํ๊ธฐ์๋ ํ๋ก๋์ธ ์ ํฐ์๋ณผ๋ผ๊ทธ | ์ ์ถ์ฑ ๋ผ๋ฏธ๋ค์ดํธ ๋ฐ ์ ์ถ์ฑ ๋ผ๋ฏธ๋ค์ดํธ ์ ์กฐ ๋ฐฉ๋ฒ |
CA2650268A1 (fr) * | 2006-05-12 | 2007-11-22 | Sca Hygiene Products Ab | Article absorbant de type culotte et procede de production d'articles absorbants de type culotte |
WO2008053199A1 (fr) * | 2006-10-30 | 2008-05-08 | Astrazeneca Ab | Thรฉrapie combinรฉe pour traiter des maladies respiratoire |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
WO2009007747A2 (fr) * | 2007-07-11 | 2009-01-15 | Astrazeneca Ab | Nouveaux composรฉs |
US20100262110A1 (en) | 2007-11-14 | 2010-10-14 | Sca Hygiene Products Ab | Method of producing an absorbent garment, and an absorbent garment produced according to the method |
US8303561B2 (en) | 2007-11-14 | 2012-11-06 | Sca Hygiene Products Ab | Method of producing an absorbent garment, and an absorbent garment produced according to the method |
FR2927330B1 (fr) * | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
BRPI0911612A2 (pt) | 2008-04-28 | 2015-12-15 | Revalesio Corp | composiรงรตes e mรฉtodos para o tratamento da esclerose mรบltipla. |
FR2944524B1 (fr) | 2009-04-17 | 2012-11-30 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
ES2525353T3 (es) * | 2009-04-28 | 2014-12-22 | Chugai Seiyaku Kabushiki Kaisha | Derivado de espiroimidazolona |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
WO2011054734A1 (fr) * | 2009-11-06 | 2011-05-12 | Basf Se | Catalyseur hรฉtรฉrogรจne contenant du fer et du manganรจse et procรฉdรฉ de fabrication d'olรฉfines par rรฉaction de monoxyde de carbone avec de l'hydrogรจne |
WO2011061527A1 (fr) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinaisons qui comprennent un modulateur du rรฉcepteur glucocorticoรฏde, destinรฉes au traitement de maladies respiratoires |
WO2011073662A1 (fr) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Association d'une benzoxazinone et d'un autre agent pour le traitement de maladies respiratoires |
US20110202284A1 (en) * | 2010-02-10 | 2011-08-18 | Mcreynolds Cristopher | Novel groups of biomarkers for diagnosing alzheimer's disease |
KR20130087002A (ko) | 2010-06-04 | 2013-08-05 | ์๋ฐ๋ ๋ชฐ๋ ํ๋ผ ๋ฆฌ์จ์น, ์ธํฌ. | ๊ธ๋ฆฌ์ ์์ก์ฒด-1 ์ ํด์ , ๊ทธ์ ์ ์กฐ ๋ฐฉ๋ฒ ๋ฐ ๊ทธ์ ์ฉ๋ |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
RU2639145C2 (ru) * | 2012-09-04 | 2017-12-20 | ะจะฐะฝั ะฐะน ะฅัะฝะถัะน ะคะฐัะผะฐััััะธะบะฐะป ะะพ., ะัะด. | ะัะพะธะทะฒะพะดะฝัะต ะพะบัะพัะธะพะธะผะธะดะฐะทะพะปะธะดะธะฝะฐ, ัะฟะพัะพะฑั ะธั ะฟะพะปััะตะฝะธั ะธ ะธั ะฟัะธะผะตะฝะตะฝะธะต ะฒ ะผะตะดะธัะธะฝะต ะฒ ะบะฐัะตััะฒะต ะธะฝะณะธะฑะธัะพัะพะฒ ะฐะฝะดัะพะณะตะฝะฝะพะณะพ ัะตัะตะฟัะพัะฐ |
MY178583A (en) | 2012-12-10 | 2020-10-16 | Chugai Pharmaceutical Co Ltd | Hydantoin derivative |
MX2016006147A (es) * | 2013-11-13 | 2016-12-09 | Hankkija Oy | Suplemento alimenticio. |
JP6227149B2 (ja) * | 2013-12-31 | 2017-11-08 | ใคใใปใณ ใใกใซใ ใฝใทใจใ ใใผใซ ใขใฏใทใชใณ ใตใณใใชใใฃใจ๏ผฉ๏ฝ๏ฝ๏ฝ ๏ฝ ๏ผฐ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผณ๏ผ๏ผก๏ผ๏ผณ๏ผ | ๆฐ่ฆใฎใคใใใพใชใธใณโ๏ผ๏ผ๏ผโใธใชใณ่ชๅฐไฝ |
EP2907512A1 (fr) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibiteurs de MMP-12 en tant qu'agents antiviraux |
CA2949023C (fr) | 2014-06-09 | 2021-10-12 | Hiroshi Noda | Composition pharmaceutique contenant un derive d'hydantoine |
KR102134171B1 (ko) | 2014-10-24 | 2020-07-15 | ๋๋์ค ๋ฐ์ด์คํ๋ง, ์ธํฌ. | ๋ํฐ์ค๋ ํฉ์ฑํจ์ c-์ ์ฌ 2-๊ณ ์น๋ฃ์ |
JO3501B1 (ar) | 2014-12-22 | 2020-07-05 | Servier Lab | ู ุดุชูุงุช 5-{(ุจูุจุฑุงุฒูู - 1-ูู)-3-ุฃููุณู - ุจุฑูุจูู}- ุฅูู ูุฏุงุฒูููุฏูู-2ุ 4 - ุฏุงููู ูู ุซุจุทุงุช ู adamts ูู ุนุงูุฌุฉ ูุดุงุดุฉ ุงูุนุธุงู ) |
CN109803961B (zh) * | 2016-09-23 | 2021-03-23 | ็ง็ ๅถ่ฏๆ ชๅผไผ็คพ | (r)-5-(3,4-ไบๆฐ่ฏๅบ)-5-[(3-็ฒๅบ-2-ๆฐงไปฃๅกๅถ-1(2h)-ๅบ)็ฒๅบ]ๅชๅ็ท-2,4-ไบ้ ฎ็ๅถ้ ๆนๆณๅ็จไบ่ฏฅๅถ้ ็ไธญ้ดไฝ |
WO2021011720A2 (fr) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Composรฉs anti-ostรฉoarthrite ainsi que compositions et mรฉthodes associรฉes |
AU2020381485A1 (en) | 2019-11-14 | 2022-06-16 | Foresee Pharmaceuticals Usa, Inc. | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof |
BR112022002387A2 (pt) | 2019-12-20 | 2022-09-06 | Landos Biopharma Inc | Composto da fรณrmula z-y-q-y' ou um sal ou รฉster farmaceuticamente aceitรกvel do mesmo |
EP4171553A1 (fr) | 2020-06-26 | 2023-05-03 | The University Of Birmingham | Inhibition de mmp-9 et mmp-12 pour le traitement d'une lรฉsion de la moelle รฉpiniรจre ou d'une lรฉsion associรฉe ร un tissu neurologique |
WO2022007866A1 (fr) * | 2020-07-09 | 2022-01-13 | ๆทฑๅณไฟก็ซๆณฐ่ฏไธ่กไปฝๆ้ๅ ฌๅธ | Dรฉrivรฉ tricyclique condensรฉ, son procรฉdรฉ de prรฉparation et son application pharmaceutique |
CN112574193B (zh) * | 2020-12-31 | 2022-05-17 | ๅไบฌๅป็งๅคงๅญฆ | ไธ็ฑปๅฃๆgsnorๆๅถๅๅๅ ถ่ฏ็ฉ็จ้ |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2327890A (en) * | 1940-04-17 | 1943-08-24 | Parke Davis & Co | Substituted phenoxyalkyl ethers |
US2745875A (en) * | 1953-06-30 | 1956-05-15 | Hoechst Ag | Preparation of nu-acylamino-phenylpropane diols |
US3452040A (en) | 1966-01-05 | 1969-06-24 | American Home Prod | 5,5-disubstituted hydantoins |
US3529019A (en) * | 1968-04-23 | 1970-09-15 | Colgate Palmolive Co | Alkylaryloxy alanines |
CS152617B1 (fr) | 1970-12-29 | 1974-02-22 | ||
CS151744B1 (fr) | 1971-01-19 | 1973-11-19 | ||
US3849574A (en) | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
GB1601310A (en) | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
JPS6172762A (ja) | 1984-09-17 | 1986-04-14 | Kanegafuchi Chem Ind Co Ltd | ๅ ๅญฆๆดปๆงใใใณใใคใณ้กใฎ่ฃฝ้ ๆณ |
JPS61212292A (ja) * | 1985-03-19 | 1986-09-20 | Mitsui Toatsu Chem Inc | ๏ผคโฮฑโใขใใ้ ธใฎ่ฃฝ้ ๆนๆณ |
CA1325222C (fr) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Procede pour la production d'acide 4-biphenylylacetique |
GB8618559D0 (en) | 1986-07-30 | 1986-09-10 | Genetics Int Inc | Rhodococcus bacterium |
JPH0279879A (ja) | 1988-09-17 | 1990-03-20 | Canon Inc | ็ปๅๅฝขๆ่ฃ ็ฝฎ |
US4983771A (en) | 1989-09-18 | 1991-01-08 | Hexcel Corporation | Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid |
NL9000386A (nl) | 1990-02-16 | 1991-09-16 | Stamicarbon | Werkwijze voor de bereiding van optisch aktief aminozuuramide. |
DK161690D0 (da) | 1990-07-05 | 1990-07-05 | Novo Nordisk As | Fremgangsmaade til fremstilling af enantiomere forbindelser |
IL99957A0 (en) | 1990-11-13 | 1992-08-18 | Merck & Co Inc | Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them |
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoร4,5-Bร-quinolin-2-one derivatives. |
US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
NL9201230A (nl) | 1992-07-09 | 1994-02-01 | Dsm Nv | Werkwijze voor de bereiding van optisch aktief methionineamide. |
EP0640594A1 (fr) | 1993-08-23 | 1995-03-01 | Fujirebio Inc. | Dรฉrivรฉ de hydantoine comme inhibiteur de mรฉtalloprotease |
JPH07105549A (ja) | 1993-09-30 | 1995-04-21 | Canon Inc | ๅ ๅญฆ็ๆ ๅ ฑ่จ้ฒๅ็ๆนๆณๅใณๅ ๅญฆ็ๆ ๅ ฑ่จ้ฒๅ็่ฃ ็ฝฎ |
CA2174650A1 (fr) | 1993-11-16 | 1995-05-26 | Mark G. Bock | Antagonistes piperidinylcamphresulfonyles de l'oxytocine |
RU2126404C1 (ru) | 1994-01-31 | 1999-02-20 | ะัะฐะนะทะตั ะะฝะบ. | 3r*, 4s* -3-[4-(4-ััะพััะตะฝะธะป-4-ะณะธะดัะพะบัะธะฟะธะฟะตัะธะดะธะฝ-1-ะธะป] ั ัะพะผะฐะฝ- 4,7-ะดะธะพะป, ะตะณะพ ะพะฟัะธัะตัะบะธะต ะธะทะพะผะตัั ะธ ัะฐัะผะฐัะตะฒัะธัะตัะบะฐั ะบะพะผะฟะพะทะธัะธั ะฝะฐ ะตะณะพ ะพัะฝะพะฒะต ะธ ัะฟะพัะพะฑั ะปะตัะตะฝะธั |
DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
ZA96211B (en) | 1995-01-12 | 1996-07-26 | Teva Pharma | Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
CZ291337B6 (cs) | 1995-11-22 | 2003-02-12 | Darwin Discovery Limited | Merkaptoalkylpeptidylovรก slouฤenina, jejรญ pouลพitรญ pro vรฝrobu pลรญpravku pro lรฉฤenรญ nebo prevenci stavu souvisejรญcรญho s metalloproteinรกzou nebo TNFalfa a farmaceutickรฝ pลรญpravek ji obsahujรญcรญ |
GB9616643D0 (en) | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1ฮฒ converting enzyme |
WO1998017645A1 (fr) * | 1996-10-22 | 1998-04-30 | Pharmacia & Upjohn Company | ACIDES ฮฑ-AMINO SULFONYLE HYDROXAMIQUES EN TANT QU'INHIBITEURS DE METALLOPROTEINASE DE MATRICE |
EP0983239A1 (fr) | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Nouveaux composes heterocycliques |
DK0877019T3 (da) | 1997-05-09 | 2002-04-08 | Hoechst Ag | Substituerede diaminocarboxylsyrer |
TR199903148T2 (xx) | 1997-06-21 | 2000-04-21 | Roche Diagnostics Gmbh | Antimetastatik ve antit๏ฟฝm๏ฟฝr etkinli๏ฟฝi olan barbit๏ฟฝrik asit t๏ฟฝrevleri. |
DE19726427A1 (de) | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
ES2189207T3 (es) | 1997-07-31 | 2003-07-01 | Abbott Lab | Inhibidores de hidroxamatos inversos de metaloproteinasas matriciales. |
TW514634B (en) | 1997-10-14 | 2002-12-21 | Lilly Co Eli | Process to make chiral compounds |
DK1030836T3 (da) * | 1997-11-12 | 2003-05-26 | Darwin Discovery Ltd | Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet |
BR9909322A (pt) | 1998-02-04 | 2000-12-05 | Novartis Ag | Derivados de sulfonilamino que inibem metaloproteinases de degradaรงรฃo de matriz |
US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
EP1077974A1 (fr) | 1998-05-14 | 2001-02-28 | Du Pont Pharmaceuticals Company | Acides hydroxamiques a substitution aryle en tant qu'inhibiteurs de metalloproteinase |
CN1295561A (zh) | 1998-06-03 | 2001-05-16 | Gpinilๆง่กๅ ฌๅธ | N๏ผๆ็ฏ็พง้ ธๆ็พง้ ธ็ญๆ็ฉ็n๏ผ็ปๅๆฐจ็ฃบ้ ฐ |
US6429213B1 (en) | 1998-06-17 | 2002-08-06 | Bristol Myers Squibb Pharma Co | Cyclic hydroxamic acids as metalloproteinase inhibitors |
FR2782082B3 (fr) | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
US6339101B1 (en) | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
JP2000127349A (ja) * | 1998-08-21 | 2000-05-09 | Komori Corp | ๅน็ๅฐๅทๆฉ |
WO2000012477A1 (fr) | 1998-08-29 | 2000-03-09 | British Biotech Pharmaceuticals Limited | Derives d'acide hydroxamique comme inhibiteurs de proteinase |
GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
CA2346288A1 (fr) | 1998-10-07 | 2000-04-13 | Yazaki Corporation | Procede sol-gel utilisant un moule poreux |
ATE260255T1 (de) | 1998-11-05 | 2004-03-15 | Pfizer Prod Inc | 5-oxo-pyrrolidine-2-carbonsรคure- hydroxamidderivate |
BR9916363A (pt) | 1998-12-18 | 2001-12-11 | Axys Pharm Inc | Composto, composiรงรฃo farmacรชutica e mรฉtodo paratratar ou prevenir um distรบrbio tromboembรณlico |
WO2000040577A1 (fr) * | 1998-12-31 | 2000-07-13 | Aventis Pharmaceuticals Inc. | Derives de 1-carboxymethyl-2-oxo-azepan utilises comme inhibiteurs selectifs de mmp-12 |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
CZ20012714A3 (cs) | 1999-01-28 | 2002-08-14 | Chugai Seiyaku Kabushiki Kaisha | Substituovanรฉ derivรกty fenetylaminu |
US6294694B1 (en) | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
GB9916562D0 (en) * | 1999-07-14 | 1999-09-15 | Pharmacia & Upjohn Spa | 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora |
US20020006920A1 (en) | 1999-07-22 | 2002-01-17 | Robinson Ralph Pelton | Arylsulfonylamino hydroxamic acid derivatives |
US6266453B1 (en) | 1999-07-26 | 2001-07-24 | Computerized Medical Systems, Inc. | Automated image fusion/alignment system and method |
ES2258431T3 (es) | 1999-08-02 | 2006-09-01 | F. Hoffmann-La Roche Ag | Proceso para la preparacion de derivados de benzotiofeno. |
US7034049B1 (en) | 1999-08-12 | 2006-04-25 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
JP3710964B2 (ja) | 1999-08-26 | 2005-10-26 | ๅฏๅฃซ้ๆ ชๅผไผ็คพ | ใใฃในใใฌใคใใใคในใฎใฌใคใขใฆใ่จญ่จๆนๆณ |
SE9904044D0 (sv) | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
CA2419008A1 (fr) | 2000-08-11 | 2003-02-11 | Kaken Pharmaceutical Co., Ltd. | Derives de l'acide 2,3-diphenylpropionique ou leurs sels, medicaments ou inhibiteurs d'adhesion cellulaire en contenant, et leur utilisation |
US20020065219A1 (en) | 2000-08-15 | 2002-05-30 | Naidu B. Narasimhulu | Water soluble thiazolyl peptide derivatives |
WO2002020515A1 (fr) | 2000-09-08 | 2002-03-14 | Abbott Laboratories | Agents antibacteriens a l'oxazolidinone |
US20020091107A1 (en) * | 2000-09-08 | 2002-07-11 | Madar David J. | Oxazolidinone antibacterial agents |
EP1191024A1 (fr) | 2000-09-22 | 2002-03-27 | Harald Tschesche | Thiadiazines et leur utilisation comme inhibiteurs de mรฉtalloproteinases |
SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US20040147573A1 (en) | 2001-03-15 | 2004-07-29 | Anders Eriksson | Metalloproteinase inhibitors |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
JP2004535411A (ja) * | 2001-05-25 | 2004-11-25 | ใใชในใใซใผใใคใคใผใบ ในใฏใคใ ใซใณใใใผ | ใใใชใใฏในใกใฟใญใใญใใใผใผๅใณ๏ผใพใใฏ๏ผด๏ผฎ๏ผฆโฮฑ่ปขๆ้ ต็ด ๏ผ๏ผด๏ผก๏ผฃ๏ผฅ๏ผใฎ้ปๅฎณๅคใจใใฆใฎใใใณใใคใณๅใณ้ข้ฃ่ค็ด ็ฐๅๅ็ฉ |
GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
CA2486350A1 (fr) | 2002-06-05 | 2003-12-24 | Kaneka Corporation | Procede de production d'un derive .alpha.-methylcysteine optiquement actif |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
SE0202693D0 (sv) | 2002-09-11 | 2002-09-11 | Astrazeneca Ab | Compounds |
SE0202692D0 (sv) | 2002-09-11 | 2002-09-11 | Astrazeneca Ab | Compounds |
GB0221250D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US6890913B2 (en) * | 2003-02-26 | 2005-05-10 | Food Industry Research And Development Institute | Chitosans |
US20040266832A1 (en) | 2003-06-26 | 2004-12-30 | Li Zheng J. | Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine |
TWI220073B (en) * | 2003-07-24 | 2004-08-01 | Au Optronics Corp | Method for manufacturing polysilicon film |
SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
SE0401763D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
TW200740769A (en) | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
TW200800954A (en) | 2006-03-16 | 2008-01-01 | Astrazeneca Ab | Novel crystal modifications |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
-
2001
- 2001-03-15 SE SE0100902A patent/SE0100902D0/xx unknown
-
2002
- 2002-03-13 EP EP02704032A patent/EP1370534A1/fr not_active Withdrawn
- 2002-03-13 RU RU2003127733/04A patent/RU2285695C2/ru not_active IP Right Cessation
- 2002-03-13 EP EP02704031A patent/EP1370556B1/fr not_active Expired - Lifetime
- 2002-03-13 EE EEP200300451A patent/EE05364B1/xx not_active IP Right Cessation
- 2002-03-13 WO PCT/SE2002/000478 patent/WO2002074751A1/fr active Application Filing
- 2002-03-13 MX MXPA03008191A patent/MXPA03008191A/es active IP Right Grant
- 2002-03-13 DE DE60213216T patent/DE60213216T2/de not_active Expired - Lifetime
- 2002-03-13 DK DK02704031T patent/DK1370556T3/da active
- 2002-03-13 CN CNA200910147512XA patent/CN101602731A/zh active Pending
- 2002-03-13 IL IL15765702A patent/IL157657A0/xx unknown
- 2002-03-13 JP JP2002573760A patent/JP4390457B2/ja not_active Expired - Fee Related
- 2002-03-13 CA CA2440473A patent/CA2440473C/fr not_active Expired - Fee Related
- 2002-03-13 WO PCT/SE2002/000472 patent/WO2002074767A1/fr active IP Right Grant
- 2002-03-13 PL PL364706A patent/PL205315B1/pl not_active IP Right Cessation
- 2002-03-13 HU HU0400194A patent/HUP0400194A3/hu unknown
- 2002-03-13 BR BR0207984-4A patent/BR0207984A/pt not_active IP Right Cessation
- 2002-03-13 HU HU0400327A patent/HUP0400327A3/hu unknown
- 2002-03-13 UA UA2003098168A patent/UA77408C2/uk unknown
- 2002-03-13 MX MXPA03008177A patent/MXPA03008177A/es active IP Right Grant
- 2002-03-13 MY MYPI20020910A patent/MY136789A/en unknown
- 2002-03-13 EE EEP200300449A patent/EE200300449A/xx unknown
- 2002-03-13 US US10/471,900 patent/US7427631B2/en not_active Expired - Fee Related
- 2002-03-13 CN CNB02809915XA patent/CN100526307C/zh not_active Expired - Fee Related
- 2002-03-13 PT PT02704031T patent/PT1370556E/pt unknown
- 2002-03-13 SI SI200230386T patent/SI1370556T1/sl unknown
- 2002-03-13 EP EP02704037A patent/EP1370537B1/fr not_active Expired - Lifetime
- 2002-03-13 US US10/471,810 patent/US7368465B2/en not_active Expired - Fee Related
- 2002-03-13 AT AT06008158T patent/ATE493406T1/de not_active IP Right Cessation
- 2002-03-13 WO PCT/SE2002/000473 patent/WO2002074748A1/fr active IP Right Grant
- 2002-03-13 DE DE60238794T patent/DE60238794D1/de not_active Expired - Lifetime
- 2002-03-13 ES ES02704031T patent/ES2267986T3/es not_active Expired - Lifetime
- 2002-03-13 AT AT02704031T patent/ATE333454T1/de active
- 2002-03-13 IL IL15765202A patent/IL157652A0/xx unknown
- 2002-03-13 CZ CZ20032499A patent/CZ20032499A3/cs unknown
- 2002-03-13 JP JP2002573776A patent/JP2004527515A/ja not_active Withdrawn
- 2002-03-13 MX MXPA03008181A patent/MXPA03008181A/es unknown
- 2002-03-13 BR BR0208104-0A patent/BR0208104A/pt not_active IP Right Cessation
- 2002-03-13 JP JP2002573757A patent/JP2004523581A/ja active Pending
- 2002-03-13 PL PL02364707A patent/PL364707A1/xx not_active Application Discontinuation
- 2002-03-13 NZ NZ528106A patent/NZ528106A/en not_active IP Right Cessation
- 2002-03-13 AT AT02704037T patent/ATE484496T1/de not_active IP Right Cessation
- 2002-03-13 US US10/471,500 patent/US20040106659A1/en not_active Abandoned
- 2002-03-13 IL IL15765602A patent/IL157656A0/xx unknown
- 2002-03-13 CN CNB028097882A patent/CN1304377C/zh not_active Expired - Fee Related
- 2002-03-13 KR KR10-2003-7011981A patent/KR20030082986A/ko not_active IP Right Cessation
- 2002-03-13 RU RU2003127735/04A patent/RU2293729C2/ru not_active IP Right Cessation
- 2002-03-13 DE DE60237965T patent/DE60237965D1/de not_active Expired - Lifetime
- 2002-03-13 KR KR1020087017665A patent/KR100879905B1/ko not_active IP Right Cessation
- 2002-03-13 EE EEP200300445A patent/EE05431B1/xx not_active IP Right Cessation
- 2002-03-13 NZ NZ528140A patent/NZ528140A/en not_active IP Right Cessation
- 2002-03-13 AU AU2002237626A patent/AU2002237626B2/en not_active Ceased
- 2002-03-13 UA UA2003098171A patent/UA78502C2/uk unknown
- 2002-03-13 CZ CZ20032497A patent/CZ20032497A3/cs unknown
- 2002-03-13 HU HU0400202A patent/HUP0400202A3/hu unknown
- 2002-03-13 BR BR0207983-6A patent/BR0207983A/pt not_active IP Right Cessation
- 2002-03-13 SK SK1095-2003A patent/SK10952003A3/sk not_active Application Discontinuation
- 2002-03-13 SK SK1096-2003A patent/SK287766B6/sk not_active IP Right Cessation
- 2002-03-13 SK SK1092-2003A patent/SK287834B6/sk not_active IP Right Cessation
- 2002-03-13 CA CA2440630A patent/CA2440630C/fr not_active Expired - Fee Related
- 2002-03-13 KR KR1020037011987A patent/KR100886315B1/ko not_active IP Right Cessation
- 2002-03-13 UA UA2003098170A patent/UA77667C2/uk unknown
- 2002-03-13 MY MYPI20020904A patent/MY136141A/en unknown
- 2002-03-13 RU RU2003127734/04A patent/RU2288228C2/ru not_active IP Right Cessation
- 2002-03-13 ES ES02704037T patent/ES2352246T3/es not_active Expired - Lifetime
- 2002-03-13 ES ES06008158T patent/ES2357138T3/es not_active Expired - Lifetime
- 2002-03-13 CZ CZ20032500A patent/CZ20032500A3/cs unknown
- 2002-03-13 KR KR10-2003-7011982A patent/KR20030082987A/ko not_active Application Discontinuation
- 2002-03-13 CN CNB02810093XA patent/CN1269804C/zh not_active Expired - Fee Related
- 2002-03-13 NZ NZ528107A patent/NZ528107A/en unknown
- 2002-03-13 CN CN2006101061525A patent/CN1962641B/zh not_active Expired - Fee Related
- 2002-03-13 PL PL02365099A patent/PL365099A1/xx unknown
- 2002-03-13 CA CA002440631A patent/CA2440631A1/fr not_active Abandoned
- 2002-03-13 AU AU2002237632A patent/AU2002237632B2/en not_active Ceased
- 2002-03-13 EP EP06008158A patent/EP1676846B1/fr not_active Expired - Lifetime
- 2002-03-15 AR ARP020100944A patent/AR035443A1/es active IP Right Grant
- 2002-03-15 AR ARP020100943A patent/AR035695A1/es unknown
-
2003
- 2003-08-28 ZA ZA200306732A patent/ZA200306732B/en unknown
- 2003-08-28 IL IL157652A patent/IL157652A/en not_active IP Right Cessation
- 2003-08-28 ZA ZA200306734A patent/ZA200306734B/en unknown
- 2003-08-28 IL IL157656A patent/IL157656A/en not_active IP Right Cessation
- 2003-08-28 ZA ZA200306731A patent/ZA200306731B/en unknown
- 2003-08-28 ZA ZA200306737A patent/ZA200306737B/en unknown
- 2003-09-09 IS IS6943A patent/IS6943A/is unknown
- 2003-09-09 IS IS6942A patent/IS6942A/is unknown
- 2003-09-10 IS IS6946A patent/IS6946A/is unknown
- 2003-09-12 NO NO20034044A patent/NO20034044L/no unknown
- 2003-09-12 NO NO20034045A patent/NO327114B1/no not_active IP Right Cessation
- 2003-09-12 NO NO20034042A patent/NO326087B1/no not_active IP Right Cessation
-
2004
- 2004-04-21 HK HK06112181.8A patent/HK1091492A1/xx not_active IP Right Cessation
- 2004-04-21 HK HK04102796A patent/HK1059932A1/xx not_active IP Right Cessation
- 2004-04-23 HK HK04102888.7A patent/HK1060121A1/xx not_active IP Right Cessation
-
2006
- 2006-10-13 CY CY20061101477T patent/CY1107525T1/el unknown
-
2007
- 2007-10-30 US US11/928,040 patent/US7625934B2/en not_active Expired - Fee Related
-
2008
- 2008-05-05 US US12/114,901 patent/US7666892B2/en not_active Expired - Fee Related
- 2008-05-06 US US12/115,785 patent/US7754750B2/en not_active Expired - Fee Related
-
2009
- 2009-11-09 JP JP2009256358A patent/JP5140058B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-26 US US12/693,852 patent/US8153673B2/en not_active Expired - Fee Related
- 2010-07-06 US US12/830,763 patent/US20110003853A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA77408C2 (en) | Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof | |
UA74624C2 (en) | Metalloproteinase inhibitors | |
AU2002237632A1 (en) | Metalloproteinase inhibitors | |
EP1370536A1 (fr) | Inhibiteurs de metalloproteinase | |
EP1444202B1 (fr) | Nouveaux inhibiteurs des metalloproteinases | |
AU2002237629A1 (en) | Metalloproteinase inhibitors |